2012
ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis
TANHÄUSEROVÁ, Veronika, Josef TOMANDL, Lukáš PÁCAL, Martin KLEPÁRNÍK, Denisa MALÚŠKOVÁ et. al.Základní údaje
Originální název
ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis
Autoři
TANHÄUSEROVÁ, Veronika (203 Česká republika, garant, domácí), Josef TOMANDL (203 Česká republika, domácí), Lukáš PÁCAL (203 Česká republika, domácí), Martin KLEPÁRNÍK (203 Česká republika, domácí), Denisa MALÚŠKOVÁ (203 Česká republika, domácí), Vendula BARTÁKOVÁ (203 Česká republika, domácí), Katarína KURICOVÁ (703 Slovensko, domácí), Jitka ŘEHOŘOVÁ (203 Česká republika), Soňa ŠTĚPÁNKOVÁ (203 Česká republika), Jan SVOJANOVSKÝ (203 Česká republika), Jindřich OLŠOVSKÝ (203 Česká republika), Jana BĚLOBRÁDKOVÁ (203 Česká republika), Darja KRUSOVÁ (203 Česká republika), Michal JURAJDA (203 Česká republika, domácí), Jan MUŽÍK (203 Česká republika, domácí), Tomáš PAVLÍK (203 Česká republika, domácí) a Kateřina KAŇKOVÁ (203 Česká republika, domácí)
Vydání
KIDNEY & BLOOD PRESSURE RESEARCH, Basel, Switzerland, Karger, 2012, 1420-4096
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30202 Endocrinology and metabolism
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 1.596
Kód RIV
RIV/00216224:14110/12:00064895
Organizační jednotka
Lékařská fakulta
UT WoS
000318486400020
Klíčová slova anglicky
asymmetric dimethylarginine; competing risk analysis; diabetic nephropathy; dimethylarginine dimethylaminohydrolase; polymorphism; symmetric dimethylarginine
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 4. 2. 2013 10:38, Ing. Mgr. Věra Pospíšilíková
Anotace
V originále
Background/Aims: Complex interplay of genetic and (patho)physiological factors influence availability of nitric oxide during the development and progression of diabetic complications. We assessed predictive value of commonly studied methylated asymmetric and symmetric dimethylarginines (ADMA and SDMA) and selected single nucleotide polymorphisms (SNPs) in dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2 genes for the progression of diabetic nephropathy (DN). Methods: A total of 341 type 1 and type 2 diabetes patients with variable degree of kidney disease were included at baseline. Plasma levels of ADMA, SDMA and L-arginine were measured and six tagging SNPs in DDAH1 and 2 were determined. Progression of DN was defined as a transition from any given stage to a more advanced stage of albuminuria. Competing risk analysis was applied. Results: Plasma levels of ADMA and SDMA significantly correlated with GFR. No significant genotype-phenotype relationship was ascertained for ADMA and DDAH variants, but SNP rs805304 exhibited marginally significant association with DN. ADMA, SDMA and L-arginine/ADMA ratio standardised to GFR were identified as significant predictors of DN progression but not GFR decline using multivariate competing risk analysis. Conclusions: In our study we confirmed potentially significant role of ADMA and SDMA for the assessment of risk of DN progression in European diabetic population.
Návaznosti
NT11405, projekt VaV |
|